Balchem Co. (NASDAQ:BCPC) Holdings Decreased by Pitcairn Co.

Pitcairn Co. reduced its position in shares of Balchem Co. (NASDAQ:BCPC) by 9.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,257 shares of the basic materials company’s stock after selling 355 shares during the period. Pitcairn Co.’s holdings in Balchem were worth $573,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BCPC. Conestoga Capital Advisors LLC raised its holdings in shares of Balchem by 1.8% during the third quarter. Conestoga Capital Advisors LLC now owns 1,175,569 shares of the basic materials company’s stock worth $206,900,000 after purchasing an additional 20,360 shares during the period. Geneva Capital Management LLC raised its stake in Balchem by 1.7% during the third quarter. Geneva Capital Management LLC now owns 779,869 shares of the basic materials company’s stock worth $137,257,000 after acquiring an additional 12,750 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Balchem by 0.9% in the second quarter. Dimensional Fund Advisors LP now owns 697,461 shares of the basic materials company’s stock worth $107,372,000 after acquiring an additional 5,977 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Balchem by 2.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 361,970 shares of the basic materials company’s stock valued at $63,707,000 after acquiring an additional 7,562 shares during the period. Finally, Congress Asset Management Co. grew its holdings in shares of Balchem by 12.4% during the third quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock valued at $53,053,000 after purchasing an additional 33,373 shares during the last quarter. 87.91% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BCPC has been the topic of a number of analyst reports. StockNews.com raised shares of Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th. HC Wainwright boosted their price objective on Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, November 4th.

Balchem Stock Up 0.1 %

Shares of Balchem stock opened at $182.69 on Tuesday. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21. Balchem Co. has a 12-month low of $120.87 and a 12-month high of $186.03. The firm has a market capitalization of $5.94 billion, a PE ratio of 49.11, a price-to-earnings-growth ratio of 5.45 and a beta of 0.65. The stock’s fifty day moving average is $173.84 and its 200-day moving average is $166.71.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.